SecBot SecBot
6-K ·Filed Jul 30, 2026

HLN

Haleon plc
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001104659-26-088450
Notable filing: 6-K
Actionable Insight ◆ Mixed

The reaffirmed FY 2026 guidance and strong adjusted EPS growth provide a positive narrative, but the reported EPS decline and large restructuring charge create uncertainty. Monitor Q3 trading statement on 29 October 2026 for organic revenue trajectory and restructuring cost realization. The $2bn debt maturity in March 2027 is the next major refinancing event.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.11
T+0 close · Jul 30, 2026 · via day close
Latest settled
+1.58%
T+60 · $10.27
Vs SPY
−0.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $10.11entry
  2. T+1 · 4mo ago −2.37%α −3.08% · $9.87
  3. T+5 · 3mo ago −0.79%α −4.41% · $10.03
  4. T+20 · 3mo ago −0.69%α −4.66% · $10.04
  5. T+60 · 25d ago +1.58%α −0.88% · $10.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Haleon reported H1 2026 results with revenue of £5,602m (+2.2% reported, +2.6% organic), adjusted operating profit up 8.2% at constant currency to £1,364m, and adjusted diluted EPS up 12.0% to 10.3p. Reported operating profit declined 2.6% to £1,172m due to £169m in restructuring costs. The FY 2026 outlook was reaffirmed: 3-5% organic revenue growth and high-single digit adjusted operating profit growth. The results show solid underlying margin expansion and strong cash generation, but reported EPS declined and the restructuring charge is significant, making the overall picture mixed.

Key Facts

  • H1 2026 reported revenue of £5,602m, up 2.2% vs H1 2025
  • Organic revenue growth of 2.6% (2.1% price, 0.5% volume/mix)
  • Reported operating profit declined 2.6% to £1,172m, impacted by £169m restructuring costs
  • Adjusted operating profit up 8.2% at constant currency to £1,364m; margin expanded 120bps to 24.3%
  • Reported diluted EPS fell 4.5% to 8.5p; adjusted diluted EPS rose 12.0% to 10.3p
  • Free cash flow of £769m, up from £734m
  • Interim dividend of 2.4p, up 9% vs prior year
  • Completed £457m of £500m share buyback allocation for 2026
  • Net debt of £7.5bn, leverage at 2.5x net debt/adjusted EBITDA
  • FY 2026 outlook unchanged: 3-5% organic revenue growth, high-single digit adjusted operating profit growth

Financial Impact

H1 2026 revenue £5,602m (+2.2% reported); adjusted operating profit £1,364m (+9.7% AER); adjusted diluted EPS 10.3p (+12.0%)

revenueoperating profitearnings per sharefree cash flownet debt

Risk Factors

  • Restructuring costs of £169m in H1 2026 may continue to weigh on reported earnings
  • Respiratory Health revenue declined 4.8% organically due to weak cold/flu season
  • North America reported revenue declined 1.1% due to FX headwinds
  • Higher effective tax rate of 25.9% vs 24.4% in prior year
  • Geopolitical disruption in Middle East impacting regional performance

Market Snapshot

Exchange
OTC
Sector
Perfumes, Cosmetics & Other Toilet Preparations
Analyst Consensus
73% bullish (26 analysts)

Investment Themes

Consumer & Retail

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-088450
Document: hln-20260630x6k.htm0001104659-26-088450
Document: 0001104659-26-088450-index-headers.html0001104659-26-088450
Document: 0001104659-26-088450-index.html0001104659-26-088450
Document: 0001104659-26-088450.txt0001104659-26-088450

US Market Status

Market Closed · Opens in 8h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026